title: Liver regional continuous chemotherapy: use of femoral or subclavian artery for percutaneous implantation of catheter-port systems.
abstract: OBJECTIVE
  To evaluate the feasibility and safety of the intraarterial chemotherapy of the liver cancer by an interventional method, catheter-port system.
  
  
  METHODS
  Thirty-two catheter-port systems were implanted percutaneously via the femoral artery or subclavian artery. Chemotherapies were performed 0-5 d after the implantation of the catheter-port systems. The mean interval between two sequential chemotherapies was 4 wk. The occurrence of side effects of the implantation was examined clinically.
  
  
  RESULTS
  Implantation of the catheter-port was successful in all patients. Mean patency period was 210 d. One occlusion (3.1%) of the catheter was observed. Displacement of the catheter was observed in one case (3.1%). One patient rated a hematoma in the chest wall as important. Mild hematoma was reported in 8 cases (25%). In 3 of 32 cases (9.4%), mild pain was reported initially, and dysesthesia was reported in seven (21.9%). No patient rated overall discomfort as mild, severe, or important.
  
  
  CONCLUSIONS
  Percutaneous placement is feasible and safe for liver regional continuous chemotherapy. Compared with surgical placement, the overall complication rate is comparable or less.
authors.affiliation: Department of General surgery, First Clinical College, Harbin Medical University, Harbin, 150001, Heilongjiang Province, China.
authors.forename: An-Long
authors.initials: AL
authors.lastname: Zhu
authors.forename: Lian-Xin
authors.initials: LX
authors.lastname: Liu
authors.forename: Da-Xun
authors.initials: DX
authors.lastname: Piao
authors.forename: Ya-Xin
authors.initials: YX
authors.lastname: Lin
authors.forename: Jin-Peng
authors.initials: JP
authors.lastname: Zhao
authors.forename: Hong-Chi
authors.initials: HC
authors.lastname: Jiang
mesh_terms: D000328:Adult; D000368:Aged; D000792:Angiography; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002408:Catheters, Indwelling / Q000009:adverse effects; D005260:Female; D005263:Femoral Artery; D006406:Hematoma; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013348:Subclavian Artery
chemical_list: D000970:Antineoplastic Agents